| アブストラクト | OBJECTIVES: To compare osteoarthritis among individuals with osteoporosis initiating romosozumab vs an active comparator. METHODS: This new user comparative effectiveness study, emulating a target trial, included individuals aged >/=50 years in the administrative claims database from 2019 to 2022. Individuals who initiated romosozumab were compared with those who initiated teriparatide. The primary outcome was the incidence of osteoarthritis, while secondary outcomes included joint-specific osteoarthritis (knee, hip, and hand) at 1 year. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between romosozumab and teriparatide users, and inverse probability of censoring weighting (IPCW) was employed to account for informative censoring. Absolute risk reduction (ARR) and relative risk (RR) at 1 year were estimated using a weighted Kaplan-Meier estimator. RESULTS: A total of 22,145 individuals were included in the study (87% female; mean age, 80 years). After IPTW-IPCW adjustment, romosozumab was associated with a lower risk of osteoarthritis compared with teriparatide (ARR, 1.1% [95% CI, 0.5%-1.8%]; RR, 0.79 [0.66, 0.89]). Joint-specific analyses showed the following results: knee osteoarthritis: ARR, 0.8% (95% CI, 0.3%-1.5%), RR, 0.79 (0.66, 0.92); hip osteoarthritis: ARR, 0.2% (95% CI, 0.0%-0.5%), RR, 0.68 (0.37, 1.05); and hand osteoarthritis: ARR, 0.2% (95% CI, 0.0%-0.4%), RR, 0.61 (0.35, 1.06). CONCLUSIONS: Romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. Similar trends were observed for hip and hand osteoarthritis; however, the differences were not significant. |
|---|
| ジャーナル名 | Annals of the rheumatic diseases |
|---|
| Pubmed追加日 | 2025/7/13 |
|---|
| 投稿者 | Hatano, Masaki; Sasabuchi, Yusuke; Okada, Akira; Kimura, Yuya; Ishikura, Hisatoshi; Tanaka, Takeyuki; Saito, Taku; Tanaka, Sakae; Yasunaga, Hideo |
|---|
| 組織名 | Department of Clinical Epidemiology and Health Economics, School of Public;Health, The University of Tokyo, Tokyo, Japan. Electronic address:;h-masaki@g.ecc.u-tokyo.ac.jp.;Department of Real-world Evidence, Graduate School of Medicine, The University of;Tokyo, Tokyo, Japan.;Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate;School of Medicine, The University of Tokyo, Tokyo, Japan.;Department of Health Services Research, Graduate School of Medicine, The;University of Tokyo, Tokyo, Japan.;Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo,;Tokyo, Japan.;Health, The University of Tokyo, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40651934/ |
|---|
